💧 Fujifilm SILVAMP TB LAM: A Breakthrough Urine Test for Tuberculosis Diagnosis in HIV Patients

 Published: May 2025   Author: Dr. Pawan Gaba

Category: Infectious Diseases | Diagnostics | Global Health

---

Introduction

Tuberculosis (TB) remains a global health threat, with over 10 million new cases and 1.3 million deaths reported annually. Diagnosing TB in people living with HIV (PLHIV) is particularly challenging due to atypical symptoms and difficulty in obtaining sputum samples. Addressing this diagnostic gap is the Fujifilm SILVAMP TB LAM (FujiLAM) test—a non-invasive, urine-based, point-of-care diagnostic tool with enhanced sensitivity and specificity for TB, especially in immunocompromised patients.

---

What Is the FujiLAM Test?

FujiLAM is an advanced urine lateral flow assay developed by Fujifilm and FIND (Foundation for Innovative New Diagnostics). It detects lipoarabinomannan (LAM), a glycolipid antigen released by Mycobacterium tuberculosis (M.tb) into the bloodstream and subsequently filtered into the urine.

While earlier LAM tests, such as the Alere Determine TB LAM Ag, showed limited sensitivity, FujiLAM integrates silver amplification technology, which boosts signal detection without compromising simplicity.

---

How It Works

1. Sample Collection: Fresh urine sample (no need for sputum).
2. LAM Detection: Uses high-affinity monoclonal antibodies and silver halide amplification to detect LAM.
3. Result: Visual detection (color development) within 60 minutes, suitable for point-of-care use.

---

Why Is It a Game-Changer?

🔬 Superior Sensitivity

• FujiLAM detects TB in patients with low CD4 counts, including those with extrapulmonary and disseminated TB, where sputum-based tests often fail.
• In WHO-endorsed evaluations, it outperforms AlereLAM by nearly 30–40% higher sensitivity.

💡 Non-Invasive and Easy

• No need for invasive procedures or laboratory infrastructure.
• Ideal for bedside testing, field clinics, and resource-limited settings.

🌍 Addresses Diagnostic Gaps in High-Burden Areas

• Especially valuable in sub-Saharan Africa and other regions with high TB-HIV coinfection rates.
• Enables faster initiation of treatment, reducing mortality among PLHIV.

---

WHO Endorsement & Policy Impact

In March 2024, the World Health Organization (WHO) conditionally recommended FujiLAM for TB diagnosis in adults and adolescents living with HIV, particularly those who are seriously ill or have low CD4 counts (<200 cells/mm³).

This aligns with End TB Strategy goals of universal access to rapid diagnostics and reducing TB-related deaths among high-risk populations.

---

Limitations & Challenges

• Availability & Cost: Full commercial rollout is still underway; pricing needs to be equitable for low-income countries.
• Temperature Sensitivity: May require stable storage conditions.
• Not a Standalone Test: Negative results do not rule out TB. Clinical judgment and additional testing may still be needed.

---

Future Outlook

• Integration into HIV care: FujiLAM has the potential to become a routine screening test in ART centers and inpatient HIV care units.
• Combination with other diagnostics (e.g., GeneXpert MTB/RIF, chest X-ray) could further enhance TB case finding.
• Operational research is ongoing to optimize rollout, quality assurance, and training for frontline health workers.

---

Conclusion

The Fujifilm SILVAMP TB LAM urine test represents a significant leap forward in TB diagnostics—providing early, accurate, and accessible detection for those who need it most. By closing the diagnostic gap for HIV-positive individuals, this innovation brings the world one step closer to ending the TB epidemic.

---

References

1. Broger T, Sossen B, du Toit E, et al. Diagnostic accuracy of a novel urine LAM test (FujiLAM) for tuberculosis: A multicentre, prospective study. The Lancet Infectious Diseases. 2020;20(12):1350–1360.

2. WHO (2024). WHO policy guidance on new TB diagnostics. Geneva.

3. FIND Diagnostics. (2024). FujiLAM: Advancing non-sputum TB testing. https://www.finddx.org